Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does SACITUZUMAB GOVITECAN Cause Hepatic failure? 6 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 6 reports of Hepatic failure have been filed in association with SACITUZUMAB GOVITECAN (TRODELVY). This represents 0.5% of all adverse event reports for SACITUZUMAB GOVITECAN.

6
Reports of Hepatic failure with SACITUZUMAB GOVITECAN
0.5%
of all SACITUZUMAB GOVITECAN reports
4
Deaths
2
Hospitalizations

How Dangerous Is Hepatic failure From SACITUZUMAB GOVITECAN?

Of the 6 reports, 4 (66.7%) resulted in death, 2 (33.3%) required hospitalization, and 1 (16.7%) were considered life-threatening.

Is Hepatic failure Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for SACITUZUMAB GOVITECAN. However, 6 reports have been filed with the FAERS database.

What Other Side Effects Does SACITUZUMAB GOVITECAN Cause?

Disease progression (389) Diarrhoea (184) Death (182) Inappropriate schedule of product administration (147) Neutropenia (128) Off label use (111) Fatigue (109) Febrile neutropenia (92) Asthenia (90) Weight decreased (89)

What Other Drugs Cause Hepatic failure?

ACETAMINOPHEN (1,392) RIBAVIRIN (888) CYCLOPHOSPHAMIDE (629) METHOTREXATE (598) BEVACIZUMAB (558) SOFOSBUVIR (525) RITUXIMAB (513) VINCRISTINE (468) DOXORUBICIN (462) PREDNISOLONE (425)

Which SACITUZUMAB GOVITECAN Alternatives Have Lower Hepatic failure Risk?

SACITUZUMAB GOVITECAN vs SACITUZUMAB GOVITECAN-HZIY SACITUZUMAB GOVITECAN vs SACROSIDASE SACITUZUMAB GOVITECAN vs SACUBITRIL SACITUZUMAB GOVITECAN vs SACUBITRIL\VALSARTAN SACITUZUMAB GOVITECAN vs SAFINAMIDE

Related Pages

SACITUZUMAB GOVITECAN Full Profile All Hepatic failure Reports All Drugs Causing Hepatic failure SACITUZUMAB GOVITECAN Demographics